Neuralink, Elon Musk’s brain-computer venture, and rivals like Max Hodak’s Science, are chasing advances in technology that ...

Elon Musk's Neuralink has been awarded breakthrough status from the FDA for an implantable chip – dubbed Blindsight – that promises to restore the sight of people with vision impairment.

The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and diabetes drug from its official shortage list and allow compounding ...

Robert F. Kennedy Jr. suggested the second Trump administration could eliminate entire departments within the Food and Drug Administration (FDA) for "corruption." The former independent ...

Blindsight, the experimental vision-restoring implant by Elon Musk’s brain-chip startup, Neuralink, has received the U.S. Food and Drug Administration’s (FDA) "breakthrough device" designation ...

Disruptedcategory Musk's Neuralink gets FDA's breakthrough device tag for 'Blindsight' implant September 18, 2024 Healthcare & Pharmaceuticalscategory Musk's Neuralink says second trial implant ...

Oct. 28, 2024 –The FDA has approved Orlynvah, a new oral treatment for uncomplicated urinary tract infections (UTIs) in women who have limited options for effective antibiotic therapy.

The US Food and Drug Administration (FDA) approved a new oral antibiotic to treat uncomplicated urinary tract infections (uUTIs). Orlynvah (sulopenem etzadroxil and probenecid) is a broad-spectrum ...

This month, Neuvivo submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for NP001 (sodium chlorite infusion). The drug has been granted orphan drug and fast track ...

The U.S. Food and Drug Administration (FDA) approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ...

FDA Says Compounding Pharmacies Can Keep Making Weight-Loss Med Tirzepatide, for Now By Robin Foster HealthDay Reporter TUESDAY, Oct. 15, 2024 (HealthDay News) -- Pharmacists may continue making ...

The FDA has agreed to review its decision to remove Eli Lilly’s LLY tirzepatide — the active ingredient used in diabetes drug Mounjaro and obesity drug Zepbound — from its shortage list.